Small molecule DUB inhibitors are emerging as promising candidates for novel anticancer therapies [39–41], but their potential role in HCC treatment remains unclear, warranting further investigation into their therapeutic mechanisms and efficacy. Here, ZUP1 is linked to hepatocellular carcinoma.